Arax Advisory Partners’s HCA Healthcare HCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.84M | Buy |
9,836
+7,845
| +394% | +$3.32M | 0.03% | 569 |
|
|
2026
Q1 | $938K | Sell |
1,991
-3,647
| -65% | -$1.84M | 0.03% | 445 |
|
|
2025
Q4 | $2.63M | Sell |
5,638
-3,880
| -41% | -$1.8M | 0.08% | 191 |
|
|
2025
Q3 | $4.06M | Buy |
9,518
+6,946
| +270% | +$2.69M | 0.06% | 275 |
|
|
2025
Q2 | $985K | Sell |
2,572
-51
| -2% | -$18.4K | 0.05% | 258 |
|
|
2025
Q1 | $906K | Sell |
2,623
-1,189
| -31% | -$382K | 0.06% | 198 |
|
|
2024
Q4 | $1.14M | Buy |
3,812
+1,929
| +102% | +$674K | 0.07% | 163 |
|
|
2024
Q3 | $765K | Sell |
1,883
-37
| -2% | -$13.5K | 0.07% | 141 |
|
|
2024
Q2 | $617K | Buy |
1,920
+180
| +10% | +$58.5K | 0.06% | 156 |
|
|
2024
Q1 | $580K | Buy |
1,740
+72
| +4% | +$22K | 0.06% | 146 |
|
|
2023
Q4 | $451K | Buy |
1,668
+476
| +40% | +$118K | 0.05% | 170 |
|
|
2023
Q3 | $293K | Sell |
1,192
-28
| -2% | -$7.66K | 0.04% | 209 |
|
|
2023
Q2 | $370K | Buy |
1,220
+26
| +2% | +$7.23K | 0.05% | 160 |
|
|
2023
Q1 | $315K | Sell |
1,194
-10
| -0.8% | -$2.54K | 0.04% | 177 |
|
|
2022
Q4 | $289K | Sell |
1,204
-62
| -5% | -$13.9K | 0.04% | 182 |
|
|
2022
Q3 | $233K | Buy |
1,266
+74
| +6% | +$14.7K | 0.04% | 189 |
|
|
2022
Q2 | $200K | Buy |
1,192
+77
| +7% | +$16.5K | 0.03% | 216 |
|
|
2022
Q1 | $280K | Sell |
1,115
-10
| -0.9% | -$2.51K | 0.04% | 196 |
|
|
2021
Q4 | $289K | Buy |
1,125
+17
| +2% | +$4.16K | 0.04% | 191 |
|
|
2021
Q3 | $269K | Sell |
1,108
-182
| -14% | -$44.5K | 0.04% | 201 |
|
|
2021
Q2 | $267K | Buy |
+1,290
| New | +$263K | 0.04% | 204 |
|
|
2020
Q4 | $216K | Sell |
1,315
-22
| -2% | -$3.22K | 0.03% | 199 |
|
|
2020
Q3 | $167K | Buy |
1,337
+360
| +37% | +$44.6K | 0.03% | 210 |
|
|
2020
Q2 | $95K | Buy |
977
+332
| +51% | +$34.5K | 0.02% | 269 |
|
|
2020
Q1 | $58K | Buy |
+645
| New | +$83.5K | 0.01% | 306 |
|
|
2018
Q3 | – | Sell |
-505
| Closed | -$51K | – | 661 |
|
|
2018
Q2 | $51K | Buy |
505
+11
| +2% | +$1.11K | 0.02% | 211 |
|
|
2018
Q1 | $47K | Sell |
494
-2
| -0.4% | -$194 | 0.02% | 207 |
|
|
2017
Q4 | $43K | Buy |
496
+11
| +2% | +$884 | 0.02% | 224 |
|
|
2017
Q3 | $38K | Sell |
485
-749
| -61% | -$60.2K | 0.02% | 237 |
|
|
2017
Q2 | $108K | Buy |
1,234
+406
| +49% | +$34.3K | 0.05% | 149 |
|
|
2017
Q1 | $73K | Buy |
828
+424
| +105% | +$35.4K | 0.04% | 158 |
|
|
2016
Q4 | $30K | Buy |
+404
| New | +$30.3K | 0.02% | 220 |
|
Other funds holding HCA
Arax Advisory Partners's HCA Position: Q2 2026 in Review
Arax Advisory Partners increased its HCA Healthcare (HCA) stake by 394% in Q2 2026, buying an estimated $3.32M and bringing the position to 9,836 shares worth $3.84M. The position accounts for 0.03% of the portfolio, ranked #569.
Arax Advisory Partners first reported a position in HCA in Q4 2016 and has held it in 32 quarters since. The position peaked at $4.06M in Q3 2025. 1,333 funds tracked by Wall St. Rank hold HCA as of Q2 2026.
- Arax Advisory Partners held 9,836 shares of HCA Healthcare worth $3.84M as of Q2 2026.
- Arax Advisory Partners bought 7,845 HCA Healthcare shares in Q2 2026, an estimated $3.32M.
- HCA Healthcare made up 0.03% of Arax Advisory Partners's portfolio in Q2 2026, its #569 holding.
- Arax Advisory Partners first reported a position in HCA Healthcare in Q4 2016 and has held it in 32 quarters since.
- Arax Advisory Partners's HCA Healthcare position peaked at $4.06M in Q3 2025.
- 1,333 funds tracked by Wall St. Rank held HCA Healthcare as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.